Daraxonrasib has emerged as a significant advancement for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), demonstrating superior survival outcomes compared to standard chemotherapy. According to data published in the New England Journal of Medicine in May 2026, the drug effectively targets RAS gene mutations, which drive cell growth in over 90 percent of pancreatic cancer cases. In a phase 3 trial, patients treated with daraxonrasib achieved a median overall survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy.
Targeting the RAS Mutation Mechanism
Most pancreatic cancers rely on the RAS gene to fuel uncontrolled cell division. In a healthy biological system, the RAS switch flips on and off to regulate cell growth. In pancreatic cancer, this switch remains permanently locked in the “on” position. Daraxonrasib functions as an oral inhibitor that binds specifically to the active, GTP-bound form of the RAS protein. By blocking this signal, the medication prevents the cancer cells from receiving the instructions necessary to continue dividing.
Did you know?
More than 90 percent of pancreatic cancers are driven by mutations in the RAS gene, making this specific pathway a primary focus for modern oncology research.
Phase 3 Trial Results and Survival Data
The clinical trial enrolled 500 patients whose cancer had already progressed following first-line chemotherapy. The results, as reported in the New England Journal of Medicine, showed that daraxonrasib reduced the risk of death by 60 percent in the RAS G12 population. Progression-free survival rates were nearly double those of the control group. Furthermore, the one-year survival rate for patients on daraxonrasib reached 53.3 percent, significantly higher than the 19 percent observed in patients treated with chemotherapy alone.
Clinical Perspective on Standard of Care
Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute and the trial’s principal investigator, emphasized the urgent need for improved second-line treatments. According to Dana-Farber, daraxonrasib is the first RAS inhibitor to be evaluated in a large, randomized trial for this patient population. Dr. Wolpin has identified the drug as a potential new standard of care for patients who have exhausted initial treatment options.
Managing Side Effects
While the efficacy of daraxonrasib is notable, the trial reported that most patients experienced treatment-related events. Common side effects included rash, mouth inflammation, nausea, and diarrhea. Researchers noted that while these events were frequent, they were generally manageable and less severe than the side effects typically associated with intensive chemotherapy regimens.
Eligibility and Access
Currently, daraxonrasib is indicated for adults with metastatic pancreatic ductal adenocarcinoma who have progressed after receiving first-line chemotherapy. It is not yet approved as a first-line treatment. However, the FDA granted expanded access to the drug in May 2026, allowing certain patients to receive the treatment ahead of formal approval. Ongoing trials are currently investigating the drug’s effectiveness in earlier stages of treatment and following surgical intervention.
Frequently Asked Questions
How does daraxonrasib differ from standard chemotherapy?
Unlike chemotherapy, which generally targets rapidly dividing cells throughout the body, daraxonrasib is a targeted therapy. It specifically binds to and blocks the active RAS protein that forces pancreatic cancer cells to grow.
Is daraxonrasib available to all pancreatic cancer patients?
No. Currently, eligibility is limited to adults with metastatic pancreatic ductal adenocarcinoma who have already undergone and progressed on first-line chemotherapy.
What is the status of FDA approval?
While formal approval is pending, the FDA granted expanded access to the drug in May 2026 for specific patients who meet the clinical criteria.
Are you or a loved one navigating a pancreatic cancer diagnosis? Stay informed on the latest breakthroughs by subscribing to our newsletter or exploring our oncology research archives for more updates on emerging therapies.
Worth a look